Suchergebnisse - (Person:"Fajgenbaum, David C")

PubPharm (9)

1

Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease

enthalten in: Blood advances | 2022

von van Rhee, F. | Rosenthal, A. | Kanhai, K. | +4

2

Adrenalitis and anasarca in idiopathic multicentric Castleman's disease

enthalten in: Lancet (London, England) | 2021

von Chen, L. | Skinnider, B. | Wilson, D. | +1

3

Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease

enthalten in: American journal of hematology | 2020

von Fajgenbaum, D. | Wu, D. | Goodman, A. | +21

4

Predictors of response to anti-IL6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease : secondary analyses of phase II clinical trial data

enthalten in: British journal of haematology | 2019

von Morra, D. | Pierson, S. | Shilling, D. | +6

5

Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease

enthalten in: Hematology. American Society of Hematology. Education Program | 2018

von Fajgenbaum, D.

6

Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease

enthalten in: Blood | 2018

von Fajgenbaum, D.

7

International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease

enthalten in: Blood | 2018

von van Rhee, F. | Voorhees, P. | Dispenzieri, A. | +39

CommentIn: Blood. 2018 Nov 15;132(20):2109-2110. - PMID 30442745

8

Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease

enthalten in: Blood | 2017

von Yu, L. | Tu, M. | Cortes, J. | +13

CommentIn: Blood. 2017 Mar 23;129(12 ):1570. - PMID 28336728

9

Siltuximab : a targeted therapy for idiopathic multicentric Castleman disease

enthalten in: Immunotherapy | 2016

von Fajgenbaum, D. | Kurzrock, R.

1
[1]